This application proposes to continue the Rocky Mountain Regional Center of Excellence (RMRCE) for Biodefense and Emerging Infectious Diseases Research located in Region VIII. The RMRCE consists of a highly integrated consortium of universities and federal agencies with significant interactions with multiple commercial entities. The RMRCE has completed three years since funding, and for the renewal, plans to build upon the strengths, synergies, and newly developed expertise that have emerged from the past efforts of this program. The renewed research program will be centered around three integrated research focus (IRF) groups that target the thematic research efforts on 1) immunomodulation, adjuvants and vaccines;2) bacterial therapeutics;and 3) viral therapeutics. The research and product development efforts of the IRF groups will be facilitated by five scientific cores. Research efforts will be directed at a variety of NIH Category A-C pathogens and will exploit the extensive BSL3 facilities within the region so that studies will be performed almost entirely with virulent forms of the pathogens. Training objectives of the RMRCE will include a competitive career development program structured similar to the NIH K-awards and group training efforts for biosafety and product development. The progress of individual projects and cores, as well as the progress and synergy of the overall program will be continually monitored and managed via a robust evaluation process that encompasses input from NIH program personnel, RMRCE leadership from multiple institutions, and external reviewers. Adding to the flexibility of this program will be the continuation of a highly successful program for the funding of Developmental Research Projects. Overall the goals of the RMRCE are summarized as: 1) continue investigator-directed research programs that address basic and translational research for biodefense and emerging infectious diseases, including understudied Select Agents;2) provide career development and group training that exploits the strengths of the RMRCE;3) utilize well integrated scientific core facilities to accelerate research and product development activities;4) enable programmatic flexibility and responsiveness through a strong project evaluation process and continuation of a program for Developmental Research Projects;and 5) establish an emergency response program that is based on the resources of the RMRCE and that is managed by a single individual.

Public Health Relevance

The RMRCE activities are directed towards fulfilling the RCE program mandate of establishing and maintaining a strong infrastructure, multifaceted basic and applied research programs, as well as translational and educational activities that will facilitate development of the next generation of therapeutics and vaccines against Category A-C and other emerging infectious disease pathogens.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DDS-M (J2))
Program Officer
Peters, Kent
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Colorado State University-Fort Collins
Schools of Veterinary Medicine
Fort Collins
United States
Zip Code
Skyberg, Jerod A; Lacey, Carolyn A (2017) Hematopoietic MyD88 and IL-18 are essential for IFN-?-dependent restriction of type A Francisella tularensis infection. J Leukoc Biol 102:1441-1450
Plumley, Brooke A; Martin, Kevin H; Borlee, Grace I et al. (2017) Thermoregulation of Biofilm Formation in Burkholderia pseudomallei Is Disrupted by Mutation of a Putative Diguanylate Cyclase. J Bacteriol 199:
Furuta, Yousuke; Komeno, Takashi; Nakamura, Takaaki (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463
Podnecky, Nicole L; Rhodes, Katherine A; Mima, Takehiko et al. (2017) Mechanisms of Resistance to Folate Pathway Inhibitors in Burkholderia pseudomallei: Deviation from the Norm. MBio 8:
Pettey, W B P; Carter, M E; Toth, D J A et al. (2017) Constructing Ebola transmission chains from West Africa and estimating model parameters using internet sources. Epidemiol Infect 145:1993-2002
Rhodes, Katherine A; Schweizer, Herbert P (2016) Antibiotic resistance in Burkholderia species. Drug Resist Updat 28:82-90
Lehman, Stephanie S; Mladinich, Katherine M; Boonyakanog, Angkana et al. (2016) Versatile nourseothricin and streptomycin/spectinomycin resistance gene cassettes and their use in chromosome integration vectors. J Microbiol Methods 129:8-13
Rico, Amber B; Phillips, Aaron T; Schountz, Tony et al. (2016) Venezuelan and western equine encephalitis virus E1 liposome antigen nucleic acid complexes protect mice from lethal challenge with multiple alphaviruses. Virology 499:30-39
Calvert, Amanda E; Dixon, Kandice L; Piper, Joseph et al. (2016) A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res 131:92-9
Westover, Jonna B; Sefing, Eric J; Bailey, Kevin W et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-8

Showing the most recent 10 out of 253 publications